BioReference LABORATORIES an OPKO Hesith Company IER, STUART C3@7@ - STUART ORSHER, M.D. 9 EAST 79TH ST, NEW YORK, NY 10021, ~ EPSTEIN, JEFFREY U/FL: Rn: Patient ID: Address: 9 GAST 71ST STREET, Bed; DOB; 61/20/1953 Age: 64 Y Sex: a | FINAL REPORT ‘Specimen ID: 104364919 te Of Report: e9/e8/2017 11:30 | Date Collected: 98/30/2017 11:58 | Date Received: 08/30/2617 23:12 NEW YORK, NY 16821 | Acct #: (C3878 P: a North America Eastern Time Notes: Non FasTING hall gz rm flags Clinical Abnormalities Summary: Glucose Cholesterol TgG BAND 41 Hemoglobin A1c 185 HI 226 HI Positive * 5.7 HI ee) Triglycerides 235 HI 1516 HI HERPES I Ab. (IgG) 7.40 HI HERPES IT Ab. (g6) ck 346 HI CHLAMYDIA AB. TgG/IgM SEE BELOW * ANA SCREEN (38) PNEUMO Ab TYPE 1 (58) PNEUMO Ab TYPE 9 (9N) (58) PNEUMO Ab TYPE 23 (23F) (58) PNEUMO Ab TYPE 68 (9V) @.4 LO (58) ANA TITER (IFA) 1:16 HI PNEUMO Ab TYP (58) PNEUMO Ab TYPE 8 (38) PNEUMO Ab TYPE 19 (19F) @.8 LO (58) PNEUMO Ab TYPE 56 (18C) 1.3 LO 0.4 LO 0.4 LO (38) PNEUMO Ab TYP} (58) (3) —/ CLINICAL REPO 5.76 HI Positive * —E 48.6 LO PNEUMO Ab TYPE 1: — 266.5 Lo B.Henselae IgG At1:64 * Total Protein ‘Albumin 45 ~315-5.2 g/dl Globulin 2.8 1.7-3.7 e/dt A/G Ratio i.6- _ LT29 ~~ — Glucose 165 HI 70-99 mg/dl Sodium Ce “135-1477 mim 17 Potassium 4.3 3.5-5.5 mmol/L Chloride 161 56-108 mmol/L 02 22 22-29 mmol/L 7.1) a |) ~ ~ B-23 ~ mg/dl Creatinine 8.92 @.86-1.30 mg/dt eGR —t—~CSST:TC(<CzCSCS 5 Or=66 mL nn €-GFR, African American 102 ror=60 mL/min ‘BUN/Creat Ratio ~~~ 21.7 7 10°6-28.6 ~ — Calcium 9.7 8.6-18.4 mg/dl Uric Acid Rg “3.4-8.5° tag 7a” “Tron 82 59-188 ug/d Bilirutin, Total 85000 ~<1.2 0-7 mg/dL Lo 235 HI 135-225 U/L “Alk Phos oO 67 — 46-156 “U/L BioReference Laboratories, Inc. 481 Edward 4, Ross De | Elmwood Park, NJ @7487 | | James Wolsberger M.D. Laboratory Director 1s Printed @9/¢8/2617 16:22 Page 1 of EFTA00299745

--=PAGE_BREAK=--

BioReference LABORATORIES an OPKO Health Company ORSHER, STUART C387@ - STUART ORSHER, M.D. 9 EAST 79TH ST, NEW YORK, NY 10021 Acet #: (C3078) MO CLINICAL REPORT AST "PHOSPHORUS ~ ALT 5 33- EPSTEIN, JEFFREY DOB: 01/20/1953 Patient ID: Address:9 EAST 71ST STREET, NEW YORK, NY 10622 274.50 <41 NOTE: The result for ALT has been confirmed by repeat analysis. ~* CARDIOVASCULAR/LIPIDS *-- Cholesterol ‘Triglycerides ~~ NOTE: The result for Triglycerides has been confirmed by repeat analysis. HDL CHOL., DIRECT TP 226 HI “1518 HE 10-71 <200 <150 >40 Age: 64 y Sex: y! FINAL REPORT Specimen ID; 164364919 Date Of Report: 09/08/2017 11:30 Date Collected: 08/30/2017 11:58 MmDate Received: North America Eastern Time ~ 88/30/2817 23:12 | | mg/ct mg/dt ] Test Not Performed: Unable to perform HDL test due to elevated Triglycerides (>1286), HDL as ® of cholesterol TNP Chol/HDL Ratio TNP "LOL7HDL Ratio TNR LDL Cholesterol Can't Calc 4 <7.4 <3,56 <168 x mg/dl NOTE: Unable to calculate LDL due to a Triglyceride level of greater than 406 me/dL. VLDL, CALCULATED Cant Calc 7-32 Can't Cale: One or more components was outside the measurable range. We are unable to calculate. Test Not Performed: One or more components were not available to perform calculation. Rac 5.15 Hee 15.4 HT oO 44.8 mcv 85.4 1 BS McHC 35.6 Le 34.9 POLYS 46.9 LuRpRS ae MONOS 7.7 BioReference Laboratories, Inc. 3.66-11.99 4.26-5.90~ 12.3-17.8 ~"39.3-52,.5 29.0-35.8 10.9-16.5 36.0-78.2 ~ 12 6-48.6 @.0-13.0 481 Edward HK, Ross Or | Elmwood Park, n2 67a¢7 | mg/d - | x16(3)/uL xi6(6)/ul James Weisberger M.D. Laboratory Director Page 2 of 15 Printed @9/¢8/2017 16:22 EFTA00299746

--=PAGE_BREAK=--

BioReference FINAL REPORT ABORATORIES an OPKO Health Company EPSTEIN, JEFFREY | DOB: 61/20/1953 Age: 64 ¥ Sex: Mm | Bea: | Specimen ID: 164364919 Date Of Report: 69/08/2017 11:3@ Date Collected: 68/30/2017 11:58 Date Received: 43/30/2017 23:12 ORSHER, STUART C376 ~ STUART ORSHER, M.D. 9 EAST 79TH ST, INEW YORK, NY 10021 Acct #: (C3878 MO iP: a INICAL REPORT idress:9 EAST 71ST STREET, NEW YORK, NY 10621 North America Eastern Time cL EOS BASOS IMMATURE GRANULOCYTES Platelet Cou *10(3)/uL Color YELLOW, STRAW, AMBER Character LER LR —y —_ Specific Gravity Ur 1.019 1.082-1.038 | "pH Urine 6.5 . . s. es ee Protein, Urine NEGATIVE NEGATIVE Gidcose, Urine “NEGATIVE ——“‘(Cist*é‘«sé«NEGAR EVES 7 — Ketone, Urine NEGATIVE NEGATIVE Urobilinogen Urine =—— 6.2-1.8 mg/dl _ , “Tt ~~ Bilirubin, Urine NEGATIVE NEGATIVE ‘Blood, Urine NEGATIVE NEGATIVE . Nitrites Urine NEGATIVE NEGATIVE Leukocyte Esterase "NEGATIVE = + NEGATIVE + |. | Crystals Urine NONE NONE | Crystal Amt. Urine “NONE +NONE PER HPF | WBC, Urine e-4 Q-4 PER HPF | RBC, Urine NONE SEEN ~~ — NONE SEEN ER HB | Epithelial Cells, Ur NONE NONE -FEW Cast, Hyaline, Urine Ss Ga BER LB ” Cast, Granular, Ur NONE SEEN @-1 PER LPF Cast, RBC, Urine . | WONE SEEN @-i ~~ *@PER LPF . Bacteria, Urine NONE NONE -FEW CULTURE, URINE NO GROWTH SITE: URINE IgG BAND 18 Negative Negative IgG BAND- 273° ~~ Negative “Negative” “kia es IgG BAND 28 Negative Negative kDa (IgG BAND 36 — “Negative ~~ Negative kDa rs rs IgG BAND 39 Negative Negative kDa | IgG BAND 4000 Positive * Negative ~ “kDa © a IgG BAND 45 Negative Negative kDa Ted’ BAND ss . Negative ~~ "Negative ~ ~~ kba . | BioReference Laboratories, Inc. James Weisberger M.D. Page 3 of 15 481 Edward H. Ross Or | Elmwood park, NJ 07407 | Laboratory Director printed @9/#8/2017 16:22 EFTA00299747

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATORIES an OPKO Health Company ORSHER, STUART EPSTEIN, JEFFREY LOOB: 01/20/1953 Age: 64 Y Sex: M PMU/FL: Bed: Specimen ID: 164364919 Date Of Report: 09/98/2017 11:30 Date Collected: 68/38/2017 11:58 Rm: Date Received: 98/30/2617 23:12 Patient ID: j Address: 9 EAST 71ST STREET, NEW YORK, NY 20823, C3076 - STUART ORSHER, M.D. | 9 EAST 79TH ST, NEW YORK, NY 10021 Acct #: (C3878) be TT CLINICAL REPORT T I i N + North America Eostern Time "BAND 66 eeu $30 Negat: _ ba SS . . . NOTE: LYME ANTIBODY (IgG) by WESTERN BLOT is considered to be positive if any § out of the following 1¢ bands are present: 18, 23, 28, 3@, 39, 41, 45, 58, 66, 93 kDa, Lyme IgG INTERPRETATION WB Negative Negative -* LYME WE, IgM W/BANDS *--- IgM BAND 23 Negative Negative kDa ‘Tg’ BAND 39° ~~" Negative Negative ~ ~ koa IgM BAND 41 Indetermin Negative kDa MOTE: LYME ANTIBODY (IgM) by WESTERN BLOT is considered to be positive if any 2 gut of the following 3 bands are present: 23, 39, 41 kDa. Lyme igh INTERPRETATION Wa Negative “Negative ~* ALLERGENS IgE *- Tg, SERUM TNP <or=114.0 Test Not Performed: Specimen is LIPEMIC. ALLERGEN INTERPRETATION: CONCENTRATION (kKUA/L) INTERPRETATION <8.10 Absent @.18 - 0.34 Very Low 0.35 - 6.69 Low 6.78 - 3.49 Moderate 3.58 - 17.49 High 17.58 + >106.08 very High * MISCELLANEOUS * Hemoglobin A1C HEMOGLOBIN Ale AND eAG REFERENCE RANGES Alc(%) OXABETES CATEGORY™ <5.7 Normal (non-diabetic) 5.7-6.4 Increased risk of diabetes =>6.5 Consistent with diabetes Alc(%) @AG(ESTIMATED AVERAGE PLASMA GLUCOSE) (mg/dL) 6 126 7 154 8 183 9 212 18 246 da 269 12 298 BioRefcrence Laboratories, Inc. James Weisberger M.D, Page 4 of 15 $81 Edward H. Ross Or | Elmwood Park, NJ 67407 | aa Laboratory Director = Printed @9/88/2017 16:22 EFTA00299748

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATORIES an OPKO Health Company ORSHER, STUART |» JEFFREY } Specimen ID: 164364919 DOB: 01/20/1953 Age: 64 Y Sex: Date OF Report: e9/08/2017 11:30 usFL: Bed: Date Collected: 68/39/2917 11:58 Rm: Date Received: 08/36/2017 23:12 9 EAST 79TH ST, Patient ID: INEW YORK, NY 16021 Address:9 GAST 71ST STREET, cet #: (C3678) NEW YORK, NY 16021 C3076 - STUART ORSHER, M.D. North America Gostern Time NOTE: The amount of glycated hemoglobin as measured by the HbAlc test may be overestimated in African Americans and should not be used as the sole parameter of glycemic burden. Similarly, hemolysis, genetic hemoglobin variants and chemically modified hemoglobin derivatives (as seen in renal failure, smoking, aspirin use) may also affect glycated hemoglobin levels. ABO/Rh BLOOD TYPE A Pos | TSH TNP @.178-4.536 ulu/mL | Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis. THYROXINE (Td) : TNP . 4.9-12.9 ug/di : T3 UPTAKE (T3U) TNP 24.3-39.8 % "THYROXINE, FREE (FT4) 9———CSCSTN ~"GTa8-1.73 nga FREE T4 INDEX TNE 1.5-3.8 TS (THYRONTNE), “FOTaL Th 72-188 ng ALBUMIN (SPEP) TNP 3.29-5.55 g/db “ALPHA-1-GLOB. (SPEP) FNP a cr > ae 7, 8 ALPHA-2-GLOB. (SPEP) TNP 6.42-6.99 a/d ‘BETA GLOB.(SPEP) . ~T ~ 6.47-1.22° °° eft ” rr “GAMMA GLOB. (SPEP) TNP . @.65-1.67 ‘g/dh MH SPIKE —_ SNP fot Betected ~~ g/d ee | SPEP GRAPH ‘TNP See Graph NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate results. Please RESUBMIT a fasting specimen at your earliest convenience. FERRITIN: TN 22-322 “ng/ml | Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis. TNP Non-Reactive TNE : ‘Non-Reactive : : rs [HEP B SURF. AB. ; “INP Non-Reactive ‘HEP, 8 SURF. AG TNP Non-Reactive ==—™S” : —— HEP. BE AB. TNP Negative ‘HEP, BE AG. TN "“"“Won-Reactive ~ rs ne: IgA, SERUM 225 70-400 mg/d “Tes, SERUM 968-1886 gd eo IgM, SERUM 46 48-238 mg/di RRO ‘Won- ~"Non-Reactive ‘Titer rs Reactive BioReference Laboratories, inc. James Weisberger M.D. Page S of 15 481 Edward H. Ross Dr | Elmwood Park, N3 67407 | Laboratory Director = Printed @9/e8/2017 16:22 EFTA00299749

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATORIES an OPK Health Company EPSTEIN, JEFFREY Specimen ID: 164364919 DOB: 03/28/1953 Age: 64 y Sex: 4 Date Of Report: 09/08/2017 12:30 U/FL: Bed: Date Collected: e8/3e/2e17 11:58 Rm ; Date Received: 68/38/2817 23:12 Patient ID: Address:9 EAST 71ST STREET, NEW YORK, NY 10821 ORSHER, STUART C3878 - STUART ORSHER, M.D. 9 EAST 79TH ST, NEW YORK, NY 10021 Acct #: (C3870) Ps North America Eastern Time CLINICAL REPORT HERPES I Ab. (IgG) : 7.40 HI INTERPRETATION OF RESULTS FOR HSV-1 AND HSV-2 IgG ANTIBODY Antibody Index Result Interpretation <8.96 AI Negative No HSV-IgG antibody detected @.58-1.89 AI Equivocal Equivocal result. Repeat in 4-6 weeks >0r=1.18 AL Positive IgG antibody detected ***Comment:This assay is type specific and will differentiate between Herpes Simplex 1 and 2 infections. Test results should be interpreted in conjunction with clinical history. The performance of this assay has not been established for pediatric populations, for neonatal screening or for testing the immunocompromised. 5.78 HI <8,98 : AT | INTERPRETATION OF RESULTS FOR HSV-1 AND HSV-2 IgG ANTIBODY Antibody Index Result Interpretation <6.98 AI Negative No HSV-IgG antibody detected 6.96-1.89 AT Equivocal Equivoceal result. Repeat in 4-6 weeks yorel.2@ AI Positive IgG antibody detected | ***Comment: This assay is type specific and will differentiate between Herpes Simplex % and 2 infections. Test results should be interpreted in conjunction with clinical history. The performance of this assay has not been established for pedietric populations, for neonatal screening or for testing the immunocompromised. TESTOSTERONE, TOT.,5. TNP 193.6-748.6 ng/dt ] NOTE: Patients receiving the drug Nandrolone cannot be tested for TESTOSTERONE, total using the EIA method (test code 379-8) due to a strong interference from the drug. Clinicians are | asked to request Testosterone, Total by LC/MS/MS (test code 3451-6) for these patients. cK ; " ~ “346 Ht 39-308 U/L H.PYLORI Ab. ,IgG 6.34 See Below HUPYLORT AB.,IgA °° ao Bow H.PYLORT Ab. , igh . 0.29 See Below “TYME DISEASE AB eg gg me |Babesia microti IgM IFA (58) <1:20 :20 ‘Pabesia microti Igo (58) <i6a | Sera from patients shown to have been infected by other tick-borne pathogens, Babesia duncani, Rickettsia rickettsii and Borrelia burgdorferi, were screened and found negative by the B. microti IgG IFA. “This test was developed and its performance characteristics determined by Viracor. Eurefins. It has not been cleared or approved by the U.S. Food and Drug Administration. Testing Performed At: Viracor Eurofins Biokeference Laboratories, Inc. Jamos Woisberger M.D. Page 6 of 15 481 Edward H. Ross Or | Elmwood Park, x2 07407 | Laboratory Director = Printed @9/88/2017 16:22 EFTA00299750

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATORIES on OPKO Health Comosny ORSHER, STUART EPSTEIN, JEFFREY Specimen ID: 164364919 DOB: 91/20/1953 Age: 64 Y Sex: m Date Of Report: 9/08/2017 11:30 U/FL: Date Collected: 68/36/2017 11:58 Rm: Date Received: 68/30/2017 23:12 9 EAST 79TH ST, Patient ID: NEW YORK, NY 10021 Address: 9 EAST 7AST STREET, Acct #: (C3@72) NEW YORK, NY 106821 Ps lial } i has _ . North America fostern Time CLINICAL REPORT C387@ - STUART ORSHER, M.D. 801 WW Technology Drive Lee's Sumnit, MO 64086 (866) 365-5198 CLIA# 26D-9983643 Tetanus Antibody IgG (58) 1.37 28.1 IU/mL “This test was developed and its performance characteristics determined by Viracor Eurofins. It has not been cleared or approved by the U.S. Food and Drug Administration. Testing Performed At: Viracor Evrofins 1601 NW Technology Drive Lee's Summit, MO 64666 CLIA# 260-9983643 Diphtheria Antibody Ig¢ (58) @.31 8.1 IU/mL I Testing Performed At: Viracor. Eurofins 26@1 NW Technology Drive Lee's Summit, MO 64086 CLIA# 260-4983643 HIV Ag/Ab TNR Non-Reactive | ] Test Not Performed: Unable to perform HIV testing, specimen is LIPEMIC. Assay Information: Assay for the detection of HIV p24 antigen and antibodies to Human Immunodeficiency Virus Type 1,including Group © {(HIV-1 + "0"} and/or Type 2 (HIV-2) Method: Chemiluminescence (Siemens Healthcare Diagnostics) CHLAMYDIA AB. Tg6/Tgh (30) SEE BELOW * , I C. pneumoniae IgM Titer <1:26 1:28 C. trach IgM Titer «1:28 <1:26 C. psittaci IgM Titer <1:28 <1:26 C. preumoniae IgG Titer 1:128 HK <1:64 Cc. trach IgG Titer <1:64 <1:64 c. psittaci IgG Titer <1:64 <1:64 --INTERPRETIVE INFORMATION: C. psittaci IgG Titer --The Chlamydia antibody test contains beth species- and genus- specific antigens, and serological cross-reactions may be seen in BioReference Laboratories, Inc. James Weisberger M.D. Page 7 of 15 481 Edward H. Ross Dr | Elmwood Park, NJ 07407 | Laboratory Director printed 99/08/2617 16:22 EFTA00299751

--=PAGE_BREAK=--

BioReference FINAL REPORT LABGQRATORIES 80 OP KO Henith Company ORSHER, STUART ) | | EPSTEIN, JEFFREY 7 DOB; 81/20/1953 Age: 64 Y Sex: m | Us/FL: Bed: { Specimen ID: 164364919 Date Of Report: 09/06/2017 11:36 Date Collected: 08/30/2817 11:58 Date Received: 98/30/2027 23:12 C3078 - STUART ORSHER, M.D. 9 EAST 79TH ST, NEW YORK, NY 10021 Acct #: (C387a) MO : CAL REPORT ldress:9 EAST 71ST STREET, NEW YORK, NY 10821 North Americo Eastern Time --both acute and convalescent samples (less than 1:128). . ~-pnheumoniae-specific reaction will exhibit titers twofold or --greater than titers observed with the C. trachomatis or Cc. ~-psittacd serology, Any IgG titer may indicate past exposure to ~-that particular species. IgG titers in recently infected --individuals are typically greater than or equal 1:512. ~-The Chlamydia microimmunofleorescent assay slides utilize C. ~-psittaci, C. pnheumonise, and nine serotypes of C. trachomatis. The -«LGV strains of C. trachomatis are not included in this assay. ~-Test. developed and characteristics determined by ARUP --Laboratories. See Compliance Statement a: aruplab.com/cs --wentaruplab.com, Julio Delgado, MD - Lab. Director 8 QUINTANA AB G/M (3a) SEE BELOW | | B. quintana Ab, IgM «4:16 -- INTERPRETIVE INFORMATION: Bartonella quintana Ab, igh «+ Less than 1:16 ...... Negative-No significant level of -- Bartonella quintena IgM antibody oun detected. «+ 1:16 or greater ..... Positive-Presence of IgM antibody -- to Bartonella quintana detected, _ Suggestive of current or recent ed infection. -~-The presence of IgM antibodies suggests recent infection. Low ~-levels of IgM antibodies may occasionally persist for more than 12 --months post-infection. --Test developed and characteristics determined by ARUP --Laboratories. See Compliance Statement A: aruplab.com/cs v-WwW.aruplab.com, Julio Delgado, MD - Lab. Director 8. quintana Ab, IgG <1:64 --INTERPRETIVE INFORMATION: Bartonella quintana Antibody, IgG -- Less than 1:64 .,,.... Negative: No significant level of -- Bartonella quintana IgG antibody ad detected. { = 1:64 - 2:128 ........ Equivocal: Questionable presence -- of Bartonella quintana IgG -- antibody detected. Repeat testing - in 16-14 days may be helpful. -- 1:256 or greater ...., Positive: Presence of IgG -- antibody to Bartonella quintana -- detected, suggestive of current ed or past infection. --A low positive suggests past exposure or infection, while high --positive results may indicate recent or current infection, but is --inconclusive for diagnosis. Seroconversion between acute and Biokeference Laboratories, Inc. James Weisberger M.D. Page 8 of 15 481 Edward H. Ross Dr | Elmwood Park, x2 07407 | J Laboratory Director printed 99/08/2017 16:22 EFTA00299752

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATORIES an OP KO Health Compony ORSHER, STUART EPSTEIN, JEFFREY DOB: @1/20/1953 Age: 64 ¥ Sex: M | Bed: Specimen ID: 164364919 Date OF Report: 09/08/2017 11:36 Date Collected: 48/30/2617 11:58 Date Received: 63/30/2817 23:12 c307@ - STUART ORSHER, [- 9 EAST 79TH ST, NEW YORK, NY 1¢@21 lacct #: (C372) P; Patient ID: idress:9 EAST 71ST STREET, NEW YORK, NY 18821 North America Eastern Time CLINICAL REPORT ~-convalescent sera is considered strong evidence of recen _-infection. The best evidence for infection is a significant change --on two appropriately timed specimens where both tests are done in --the same laboratory at the same time. --Test developed and characteristics determined by ARUP --Laboratories. See Compliance Statement A: aruplab.com/CS HEP. ¢ Ab. ‘TNP Non-Reactive ] | Test Not Performed: Wa were unable to perform the Hepatitis test(s) requested due to lipemia. Please resubmit 2 fasting specimen. HEP ¢ Ab. (S/CO RATIO) TNP <6.88 | (36) Performed by: ARUP 506 Chipeta Way Salt Lake City, UT #84168 (58) Performed by: Viracor Eurofins Clinical Diagnostic 1661 NW Technology Drive Lees Summit, MO 64886 Test Not Performed: One or more components were not available : to perform calculation. H.PYLORI (IgG, Iga, IgM) REFERENCE RANGES RESULT (UNITS) INTERPRETATION <8.89 NEGATIVE @.89-0.99 EQUTVOCAL 20.99 POSITIVE NOTE: This is a screening test for H.PYLORI. The diagnosis of gastritis and peptic ulcers should be assessed with the patients medical history and clinical symptoms. Results in the equivocal range should be rechecked with a new specimen in 2-5 weeks. NOTE: The H. Pylori, IgM test was developed and its performance characteristics were determined by BioReference Laboratories. Tt has not been cleared by the U.S. Food and Orug Adminis tration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research, This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform this test. ASSAY INFORMATION: Method ELISA NOTE: A result of equivocal or positive for 8.burgdorferid (Lyme Ab) should not be interpreted without supplemental Western Blot testing. **Lyme Antibody ranges (IgG/Igm)** <6.91 » Negative @.91-1.89 = Equivocal BioReference Laboratories, Inc. James Weisberger M.D. Page 9 of 15 481 Edward H. Ross Dr | Elmwood Park, N2 07967 | iy Laboratory Director Printed @9/88/2617 16:22 EFTA00299753

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATORIES on QPKO Health Comeany EPSTEIN, JEFFREY ORSHER, STUART DOB: @1/20/2953 Age: 64 Y Sex: m Date OF Report: 69/e8/2017 11:38 U/FL: Bed: Date Collected: 68/38/2617 11:58 | Rim: ] Date Received; 08/39/2017 23:12 Specimen ID: 104364919 €3@78 - STUART ORSHER, M.D. S EAST 73TH ST, NEW YORK, NY 10021 Acct #: (C3076) MO | °: Patient ID: Address: 9 EAST 71ST STREET, NEW YORK, NY 10621 Py North America Eastern Time = Positive Hepatitis 8 Result Interpretation (for reference use only) Marker LT/EA* Acute Past Chronic HBV Vacc. FEES SEH T REE EEREEEDES SES EMRE TEETER ESSERE EERE SS CRORE KES E EET ERE HBsAg + + - + - HBeAg + + - +/- - HEP. B.CORE AB, IgM - + . 7 . HEP.B.CORE AB. - + + + - HBeAb - - +/- +/- - HBsAb - - o/s - + *Late Incubation/Early acute NOTE: In remote past infection, HBsAb level may be Negative or Non-Reactive in some patients. ANA SCREEN Positive © Negs<1:8@ | cP 8.2 <@.5 mg/dL "ESR (Sed-Ratey pi ~ oo FOLIC ACID TNP 25.38 ng/me Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis. : Folic Acid Range Units (ng/mi) Norma]. >5.38 Borderline deficient 3.38-5,38 Deficient 8.35-3.37 Excessive 224.88 VITAMIN ‘B12 TNP 214-911 pe/al | | Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis. 250H, VITAMIN D TNP 32.6-160.8 ng/mL ] Test Not Performed: Unable to perform testing, specimen is LIPEMIC, ' VITAMIN D,25-O0H TEST INFORMATION Range (ng/mL) Suggested Interpretation <28.8 Deficient 28,.6-31.9 Insufficient 32,0-188.8 Sufficient 2100.8 Possible Adverse Effects ‘VIT D1, ZS50THYGROXY TP : 19.9-79.3 pa/me Test Not Performed: Unable to perform testing, specimen is LIPEMIC. BioReference Laboratories, Inc. James Weisberger M.D. Page 16 of 15 482 Edward H. Ross Dr | Elewood Park, N? 07407 | nT Laboratory Director printed 09/@8/2017 16:22 EFTA00299754

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATORIES en QIPKO Health Company JORSHER, STUART ] } DOB: 01/20/1953 Age: 64 Y Sex: M Date OF Report: 99/e8/2017 11:3¢ UsFL: Bed: Date Collected: 68/36/2017 11:58 Rm: Date Received: 98/30/2817 23:12 Patient ID: Address:9 EAST 71ST STREET, NEW YORK, NY 16021 Specimen ID: 164364919 yc3678 - STUART ORSHER, M.D. mS EAST 79TH ST, GENEW YORK, NY 10021 mAcct #: (C3678) Ps North America Eastern Time CLINICAL REPORT MUMPS VIRUS Ab. (IgG) 3.87 Imenune=>1.289 TEMD; BiGOD (CHILD) nee Below RANGES ‘FOR LEAD, BLOOD Reference Range (ug/dL) Adult/Child <5.6 Occupational <40.8 NOTE: Lead risk guidelines conform to CDC Guidelines, BioReference is an OSHA-APPROVED lab for lead testing. NOTE: Blood lead levels in the range $.@-9.9 ug/dl have been associated with adverse health effects in children aged 6 years and younger. NOTE: BI]. Lead results =/>5.@ ug/dL are confirmed by repeat analysis. NOTE: Capillary and microtainer blood levels =/>5.@ ug/dl may be due to contamination from lead found on the finger surface and requires confirmation on venous blood. | NOTE: This test for LEAD was developed and its performance characteristics were determined by Biokeference Laboratories. It has not been cleared by the U.S. Food and Drug Admanistration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This leb has been approved by CLIA $8 and designated as a high complexity laboratory and is qualified to perform this test. ASSAY INFORMATION: ICP-MS Immunotyping, Serum TNP Negative | NOTE: Specimen submitted is LIPEMIC. This may cause inaccurate results. Please RESUBMIT a fasting specimen at your earliest convenience. MERCURY, BLOOD (30) . 8 , 6-10 ug/L “| INTERPRETIVE INFORMATION: Mercury, Blood Blood mercury levels predominantly reflect recent exposure and are mast useful in the diagnosis of acute poisoning as blood mercury concerttrations rise sharply and fall quickly over several days after ingestion. Blood concentrations in unexposed individuals rarely exceed 26 ug/L. The provided reference interval relates to inorganic mercury concentrations. Dietary and non-occupational expasure to organic mercury forms may contribute to an elevated total mercury result. Clinical presentation after toxic exposure to organic mercury may include dysarthria, ataxia and constricted vision fields with mercury blood concentrations from 28 to 5@ vug/t. Test developed and characteristics determined by ARUP Laboratories. See Compliance Stetement 8: aruplab.com/CS ww.aruplab.com, Julio Delgado, MD - Lab. Director RUBEOLA/MEASLES (IgG) 1.82 Immune=>1,@9 | Biokeference Laboratories, Inc. James Woisberger M.D, Page il of 15 431 Edword H. Ross Dr | Elmwood Park, no 07507 | [RRM ERR Laboratory Director Printed 29/08/2017 16:22 EFTA00299755

--=PAGE_BREAK=--

BioReference LABORATORIES an OPKO Health Company FINAL REPORT ORSHER, STUART EPSTEIN, JEFFREY IDOB: 61/20/1953 Age: 64 Y Sex: M Specimen ID: 104364919 Date OF Report: 09/88/2017 11:30 Date Collected: e8/3e/2017 11:53 | Date Received: 98/30/2017 23:12 3078 - STUART ORSHER, [i ma? EAST 79TH ST, Address: 9 EAST 71ST STREET, NEW YORK, NY 10821 North America Eastern Time CLINICAL REPORT VARICELLA ZOSTER, IgM (3) < 6.91 REFERENCE RANGE for Varicella-zoster Igm Abs: Less than 6.91 ....... +++ Negative @.91 -~ 1.09 ..... . -Equivocal Greater than 1.69 .......+.-.+-Positive Results from any one IgM assay should not be used as a sole determinant of @ current or recent infection. Because an IgM test can yield false positive results and low levels of IgM antibody may persist for more than 12 months post infection, reliance on a single test result could be misleading. acute infection is best diagnosed by demonstrating the conversion of IgG from negative to positive. If an acute infection is suspected, consider obtaining 2 new specimen and submit for both IgG and Igm testing in two or more weeks. VARICELLA ZOS. (IgG) 3.46 Immune=>1.@9 “PTH(3), INTACT TNP “" “3.8-85.¢ pe/al Te a Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis. RHEUMATOID (RF) TITER <18 <14 Tu/m RUBELLA, IgG ‘Tmmune=>9.9° u/at | es Test Not Performed: Specimen rejected for testing due to moderate or marked hemolysis. INTERPRETATION OF RESULTS FOR RUBELLA IgG ANTIBODY Results (IU/mL) Interpretation < 5.8 Negative Non-Immune 5.8 - 39.9 Equivocal Retest > o.9 Positive Immune NOTE: Results interpreted as EQUIVOCAL indicate a level of antibody below the Positive (Immune) cut off. Repeat testing on 2 new specimen is Suggested to assess antibody response after a booster shot or a viral syndrome. | ASSAY INFORMATION: Method Chemiluminescence (Siemens Diagnostics) ANA TITER (IFA) 1:16@ HI <1:80 Titer | ANA PATTERN = HOMOGENEOUS AND SPECKLED Antibodies To Association Frequency ANA Screening test for SLE in symptomatic patients. 95-100% (antinuclear Ab, BioReference Laboratartes, Inc. James Weisberger M.D. Page 12 of 15 481 Edward H. Ross Dr | Elmwood Park, NJ 07407 | Laboratory Director Printed 68/08/2617 16:22 EFTA00299756

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATORIES sr OPKO Health Compory ORSHER, STUART | Specimen ID: 164364919 EPSTEIN, JEFFREY | DOB: 01/20/1953 Age: 64 Y Sex: M | Date Of Report: 09/e8/2617 11:30 U/FL: Bed: Date Collected: 88/34/2017 11:58 Rm: Date Received: 68/34/2017 23:12 Patient ID: Ig EAST 79TH ST, K Address:9 EAST 71ST STREET INEW YORK, NY 10621 NEW ORK ao” mmaer, Acct #: (C3072 moO | Pr a CLINICAL REPORT c3a7@ - STUART ORSHER, I. North America Eastern Time ANA Assist with diagnosis of Scleroderma (Systemic Sclerosis). 68-80% ANA Sjogren's Syndrome. 48-78% ANA Idiopathic Inflammatory Polymyositis or Dermatomyositis. 30-88% dsDNA Characteristic of SLE, Rare in other CTDs. Highly 25-85% associated with active disease. Sm(Smith) Highly specific for SLE. Uncommon in other diseases. 15-30% S$ A (Ro) associated with SLE, Neonatal Lupus and Sjogren's Syndrome. 35-68% $$ 8 (La) Associated with SLE. 15% SS B (La) Associated with Sjogren's Syndrome. 48-68% $cl-78 (anti DNA Topoisomerase) Associated with Diffuse Scleroderma 34-48% and rarely co exists with anti-Centromere Abs which are associated with Limited Scleroderma Disease. Jo-1 Associated with Polymyositis or Dermatomyositis. 20-25% Centromere Identified by staining pattern. Their presence is 8B% associated with CREST Syndrome (Limited Systemic Sclerosis). V1 nRNP Used to categorize Mixed Connective Tissue Disease (MCTD). High Correlation Histone Proteins (Chromatin) Associated with drug induced LE. 9a-180% ref:Kavanaugh,A(et al.):Guidelines for Clinical Use of the Antinuclear Antibody Test and Tests for Specific Autoantibodies to Nuclear Antigens. Arch.Pathol Lab Med. Vol.124,Jan 2006. PNEUMO ‘AB TYPE 1 (58) <8.310 1.3 ~~ pdm | PNEUMO Ab TYPE 3 (58) 1.4 1.3 ug/mL PNEUMO Ab TYPE 4 (58) on 8.6 LO ALB 7) | ee ~~ “PNEUMO Ab TYPE 8 (58) 0.4 LO >1.3 ug/al ‘PNEUMO Ab TYPE 9 (SN) (58) @410 1.3 ug/ml ” ~~ PNEUMO Ab TYPE 12 (12F) (58) <0.3 >1.3 ug/m ‘PNEUMO Ab TYPE 14 (58) => ae ~ 31.30 ug oe a PNEUMO Ab TYPE 19 (19F) (58) 8.8 LO 21.3 ug/mL PHEUMO Ab TVPE 23 (23F) (88) <0.3 10 33 g/m a a |PNEUMO Ab TYPE 26 (68) (58) @.5 LO 21.3 ug/mL SNEUMO Ab TYPES G58) Bg ~— PNEUMO Ab TYPE 51 (7F) (58) 1.5 >1.3 ug/mk “PNEOMO “Ab TYPE 56 (asc) (58) Rw cS oe Vein rs PNEUMO Ab TYPE 68 (9V) (58) 2.4 LO 31.3 ug/mL Testing Performed At: Viracor Eurofins 1601 Nw Technology Drive Lee's Summit, MO 64086 CLIA# 26D-9983643 “ARSENTE, BLOOD 2 rr: rs 7) Ses | “— | Biokeference Laboratories, Inc. James Wolsberger M.D, Page 13 of 415 431 Edward H. Ross Dr | Elmwood Park, NJ 874@7 | Him Laboratory Director Printed 69/68/2017 16:22 EFTA00299757

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATOR es an OPKO Hesith Company EPSTEIN, JEFFREY ] Specimen ID: 164364919 DOB: 91/28/1953 Age: 64 Y Sex: Date Of Report: 09/68/2017 11:30 U/FL: Bed: Date Collected: a8/3¢/2017 11:58 Rm: Date Received: 98/3@/2@17 23:12 Patient ID; Address: 9 EAST 71ST STREET, NEW YORK, NY 20822 | 2 NEW YORK, NY 10021 : (€3@7@) Mo >: TT | CLINICAL REPORT North America astern Time A.Phagocytophila IgG Ab (24) <1:6 A.Phagocytophila Igh Ab (24) <i:28—— B.Henselae IgG Ab (3) 1:64 * < 1:64 titer o. ae a B.Henselae IgM Ab (3) AO cs ty) rs 21. . , This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Valencia. It has not been cleared or approved by the US Food and Drug Administration. This assay has been validsted pursuant to the CLIA regulations and is used for clinical purposes, Interpretation (24) SEE NOTE | ANTIBODY NOT DETECTED REFERENCE RANGE IgG <2:64 Igh <1:28 Anaplasma phagocytophilum is the tick-borne agent causing Human Granulocytic Ehrlichiosis (HGE). HGE is distinct and separate from Human Monocytic Ehrlichiosis (HME), caused by Ehrlichia chaffeensis. Serologic crossreactivity between A. phagocytophilum and &. chaffeensis is minimal ($-15%). This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Infectious Disease. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. Quest Infectious Disease 33688 Ortega Hwy (3) Performed by: Quest Diagnostics Nichols Institute of Valencia 27027 Tourney Road Valencia, CA 91355-5386 (24) Performed by: Quest Infectious Disease 33608 Ortega Highway San Juan Capistrano, CA 92675 “medical Director Hollis 1. Batterman, MD (30) Performed by: ARUP 588 Chipeta way Salt Lake City, UT 84108 (58) Performed by: Viracor Eurofins Clinical Diagnostic BioReference Laboratories, Inc. James Wolsbarger M.D, Page 14 of =15 481 Edward H. Ross Or | Elmwood Park, x2 e7ae7 | ST Laboratory Director Printed @9/e8/2617 16:22 EFTA00299758

--=PAGE_BREAK=--

BioReference FINAL REPORT LABORATORIES 20 OPK Hesith Company ORSHER, STUART —-- -——__. EPSTEIN, JEFFREY DOB: 1/20/1953 Age: 64 Y Sex: | : Bea: Specimen ID: 104264939 Date Of Report: 09/08/2017 11:30 Date Collected: 08/30/2017 11:53 Date Received: 98/3¢/2017 23:12 Patient ID: idress:9 EAST 71ST STREET, NEW YORK, NY 10821 Bm Acct #: (C3870) Mo North America Eastern Time Lees Summit, MO 64886 INTERPRETATION OF RESULTS FOR RUBEOLA(MEASLES) ,MUMPS ,VARICELLA VIRUS ABS. Range Interpretation < or = @.96 Negative Non Immune ®.91 - 1.69 Equivocal Retest > or = 1.18 Positive Immune Results interpreted as EQUIVOCAL indicate a level of antibody below the positive (Immune) cut off. Repeat testing on a new specimen is suggested to assess antibody response after a booster shot or 2 viral syndrome. NOTE: The following tests: SERUM SELENIUM, SERUM CHROMIUM, ARSENIC BLOOD and CADMIUM BLOOD were developed and their performance characteristics were determined by BioReference Laboratories. They have not been cleared by the U.S. Food and Orug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research, This lab has been approved by CLIA 88 and designated as a high complexity laboratory and is qualified to perform these tests. NOTE: The specimen submitted was MARKEDLY hemolyzed. Some results may be affected. Please resubsit as needed. NOTE: Specimen submitted is LIPEMIC. This may Cause inaccurate results. Please resubmit a fasting specimen at your earliest convenience. BioReference Laboratories, Inc. James Weisberger M.D. Page 15 of 15 481 Edward H. Ross Or | Elmwood Park, NI @7487 | A Laboratory Director = Printed @9/¢8/2017 16:22 EFTA00299759